Logo image
A new era in the treatment of multiple sclerosis
Journal article   Peer reviewed

A new era in the treatment of multiple sclerosis

S.A. Broadley, M.H. Barnett, M. Boggild, B.J. Brew, H. Butzkueven, R. Heard, S. Hodgkinson, A.G. Kermode, J. Lechner-Scott, R.A.L. Macdonell, …
The Medical Journal of Australia, Vol.203(3), pp.139-141
2015
url
Free to Read *No subscription requiredView

Abstract

• Multiple sclerosis (MS) is an autoimmune disease of the central nervous system with a multifactorial aetiology and highly variable natural history. • A growing understanding of the immunopathogenesis of the condition has led to an expanding array of therapies for this previously untreatable disease. • While a cure for MS remains elusive, the potential to reduce inflammatory disease activity by preventing relapses and minimising disease progression is achievable. • The importance of early treatment in minimising long-term disability is increasingly recognised. • Most of the newer, more effective therapies are associated with risks and practical problems that necessitate an active management strategy and continuous vigilance. • While the initiation of these therapies is likely to remain the responsibility of neurologists, other specialist physicians and general practitioners will be involved in the identification and management of adverse effects.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.203 Neuromuscular Disorders
1.203.147 Multiple Sclerosis
Web Of Science research areas
Clinical Neurology
ESI research areas
Clinical Medicine
Logo image